Given the accelerated pace of drug development in recent years, medical writing is now considered part of the critical path in expedited programmes rather than as a support function. Expectations around document development speed, parallel authoring, review cycles, and submission readiness have increased. This article explores what expedited medical writing timelines mean in practice, the challenges this creates, and the strategies that enable sponsors to meet aggressive submission goals without compromising regulatory standards.